PAP
ORIC icon

Persistent Asset Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Persistent Asset Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,373
Closed -$76.8K – 202
2024
Q4 		$76.8K Buy
+7,373
New +$67.6K 0.06% 105

Other funds holding ORIC

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Persistent Asset Partners's ORIC Position: Q1 2025 in Review

Persistent Asset Partners sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 7,373 shares — an estimated $76.8K sold.

Persistent Asset Partners first reported a position in ORIC in Q4 2024 and held it in 1 quarter. The position peaked at $76.8K in Q4 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

  • Persistent Asset Partners reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 7,373 Oric Pharmaceuticals shares in Q1 2025, an estimated $76.8K.
  • Persistent Asset Partners first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Persistent Asset Partners's Oric Pharmaceuticals position peaked at $76.8K in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Persistent Asset Partners's 13F filing for Q1 2025, filed 13 May 2025.